A sermorelin and ipamorelin blend is usually sold as one vial holding both peptides as a dry powder, mixed with bacteriostatic water and injected as a single shot at night. The pitch is that two different signals reach the pituitary at once, so it releases more growth hormone than either would draw out alone. That idea has a real basis. The product built on it has never been tested.
Why combine sermorelin with ipamorelin?
The two drugs pull different levers. Sermorelin copies GHRH, the hypothalamic hormone that tells the pituitary to release; ipamorelin copies ghrelin, which acts on a separate receptor on the same cells. Ipamorelin was chosen over older ghrelin mimetics because, in animal studies, it released growth hormone without the cortisol and ACTH rise seen with GHRP-2 and GHRP-6 [2]. How the wider family divides is mapped in growth hormone peptides.
The two also keep similar hours. In sermorelin’s adult trial, a bedtime injection released growth hormone within 10 minutes, and the burst lasted about 2 hours [1]. In healthy volunteers given ipamorelin by infusion, growth hormone peaked at about 40 minutes and the drug’s half-life was 2 hours [3]. Two short pulses timed together is the whole rationale for one syringe.
Does sermorelin work better with ipamorelin?
For one acute pulse of growth hormone, the class-level answer is probably yes. At the Mayo Clinic, 47 men aged 18 to 74 received GHRH and the ghrelin mimetic GHRP-2 as simultaneous infusions, and the strength of the combined response tracked their age, abdominal fat and IGF-1 level; those three together accounted for 60% of how much the synergy varied between men [4]. Older men and men carrying more visceral fat got less of a boost from the pair.
Notice what that study did not use: sermorelin, ipamorelin, under-the-skin injection, or more than one session. Whether the pair does better over weeks, on anything a person would feel or measure, has not been studied. The general problem with reading a mechanism study as a product result is covered in how to read a peptide study.
Has the combination ever been tested?
No. PubMed holds five records that name both sermorelin and ipamorelin. All five are reviews, mostly surveys of peptides used in sport and self-administration, and none reports a trial of the two given together [6]. Restricting the same search to clinical trials returns zero. The broader version of that census, including CJC-1295, is in sermorelin stacks; for this pairing the answer is simply that no one has published a human result.
What has ipamorelin alone been tested for?
Two human studies, neither about muscle, fat or aging. A 1999 study dosed healthy men at five escalating infusion rates to map how the drug moves through the body and how much growth hormone it releases [3]. A 2014 randomized trial tested it after bowel surgery, to speed the return of gut function. Across 114 patients, adverse events were common in both arms, 87.5% with ipamorelin vs. 94.8% with placebo, and the time to a first tolerated solid meal (25.3 vs. 32.6 hours) was not significantly different (p = 0.15) [5].
Sermorelin’s own human base is a single 16-week trial in 19 adults aged 55 to 71, with more lean mass in the men and not in the women [1]. A blend therefore combines one drug with thin outcome data and one with none for the uses it is sold for. The single-agent comparison is in sermorelin vs. ipamorelin.
What is the sermorelin and ipamorelin dosage in a blend?
There is no tested ratio, so every blend dose is a seller’s choice. The most common premixed vial sold online lists 10 mg in total, 5 mg of each peptide, from research-chemical vendors whose own pages state it is for laboratory research only and not for human consumption. A 50/50 split by weight is a manufacturing convenience; it does not come from a study.
The trial doses do not translate either. Sermorelin’s adult trial used 10 mcg per kilogram injected nightly [1], which the dose-by-weight tool converts for your weight. Ipamorelin’s surgery trial used 0.03 mg per kilogram by intravenous infusion twice a day [5], a different route for a different purpose. Neither number tells you what a combined nightly shot should contain, and anyone mixing a blend vial has one concentration for two drugs. The reconstitution calculator handles the arithmetic for sermorelin on its own.
Is a sermorelin and ipamorelin blend legal to compound in 2026?
The sermorelin half is straightforward; the ipamorelin half is not. On FDA’s Category 2 page, updated April 22, 2026, ipamorelin acetate remains in Category 2 for outsourcing facilities and is listed as withdrawn on the pharmacy side [7]. Withdrawal is not approval. In 2024 FDA found that ipamorelin has no USP monograph and is not a component of any approved drug, and recommended against adding it to the list pharmacies may compound from [8]. FDA’s Category 2 entry also cites serious adverse events, including death, in a published study where ipamorelin was given intravenously for gut motility [7].
Some prescribers have drawn their own line. Tactus Health, for example, prescribes sermorelin and declines ipamorelin on regulatory grounds, as the Tactus Health review describes. The full 2026 picture for sermorelin is in sermorelin’s legal status in 2026.
What side effects are possible?
The expected ones are those of each drug plus whatever extra growth hormone the pair produces: injection-site redness, flushing, headache, fluid retention and joint aches. Sermorelin’s trial reported a temporary rise in blood lipids as its only adverse effect [1], and the wider picture is in sermorelin’s side effects. For ipamorelin, FDA’s concern is about the material as much as the molecule: it flags a risk of immune reactions from aggregated peptide and impurities, made harder to check because ipamorelin contains unnatural amino acids [7]. Two peptides in one vial means two sets of impurities, and a research-chemical vial comes with no pharmacy accountable for either.
How do blend prices compare with sermorelin alone?
Prescription sermorelin injections run $99 to $349 a month across the 68 sellers that publish a monthly injection price, read August to October 2026. A research-chemical blend vial is cheaper on its face because it carries no prescription, no prescriber and no pharmacy; it is not the same product at a lower price. A prescription blend has to clear the ipamorelin problem above before its price means anything, so the useful comparison for most readers is between sermorelin sellers, starting with the sermorelin injections board.